5 Implementation

5 Implementation

5.1 The Secretary of State and the Welsh Assembly Minister for Health and Social Services have issued directions to the NHS in England and Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends use of a drug or treatment, or other technology, the NHS must usually provide funding and resources for it within 3 months of the guidance being published. If the Department of Health issues a variation to the 3-month funding direction, details will be available on the NICE website. When there is no NICE technology appraisal guidance on a drug, treatment or other technology, decisions on funding should be made locally.

5.2 The Department of Health and the manufacturer have agreed that romiplostim will be available to the NHS with a patient access scheme which makes romiplostim available with a discount on the 250 microgram vial. The size of the discount is commercial in confidence. It is the responsibility of the manufacturer to communicate details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to the manufacturer at the following e-mail address: nplate-nicepas@amgen.com.

5.3 NICE has developed tools to help organisations put this guidance into practice (listed below).

  • Costing report and costing template to estimate the national and local savings and costs associated with implementation.

  • Audit support for monitoring local practice.

  • National Institute for Health and Care Excellence (NICE)